Report Name: Adcock Ingram Holdings Limited Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
ADCOCK INGRAM HOLDINGS LIMITED Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
ADCOCK INGRAM HOLDINGS LIMITED – Business Description:
Adcock Ingram Holdings Limited is engaged in manufacturing and marketing a range of healthcare products. The company has operations in South Africa, Namibia, Ghana, Sierra Leone and India. The company operates through five business segments which include over the counter, prescription, hospital and consumer. The company’s prescription business segment offers pharmaceutical products that are available only on prescription. Adcock offers pharmaceuticals related to women’s health and urology, pain, generics, cardiovascular, dermatology, central nervous system (CNS), Gastrointestinal, antiretroviral (ARV) and ophthalmic. The company offers products under the brand names of Trivenz, Genpayne, Adco-Zolpidem, Myprodol, Estrofem, Cipralex (Lundbeck), Adco-Simvastatin, Lamivudine/Zidovudine, Adco-Efavirenz and Xylotox. In FY2017, the company’s prescription business segment generated revenues of ZAR1,937.9 million, which accounted for 33.6% of company’s total revenue excluding adjustments and eliminations. Adcock’s over the counter business segment offers pharmaceutical products that are available without prescription. It also offers personal care products. The company offers a range of over the counter products related to pain, cold and cough, allergy, heartburn and indigestion and energy. Adcock offers over the counter products under the brand names of Adco-Dol, Corenza C, Allergex, BronCleer, Citro-Soda, Alcophyllex, Betapyn, Dilinct, Napamol and Solphyllex. In FY2017, the company’s over the counter business segment generated revenues of ZAR1,849 million, which accounted for 32.2% of company’s excluding adjustments and eliminations. Adcock’s hospital business segment is engaged in supplying critical care products such as intravenous fluids, blood bags, renal dialysis products and small-volume parenterals. In FY2017, the company’s hospital business segment generated revenues of ZAR1,256.7 million, which accounted for 21.8% of company’s total revenue excluding adjustments and eliminations. The company’s consumer segment is engaged in fast moving consumer goods. It offers products related to analgesics, cough, colds, flu and congestion, digestive well-being, energy, vitamins, minerals and supplements, and feminine hygiene. The company offers products under the brand Panado, Bioplus, Probiflora, Compral, Cepacol, GynaGuard, ViralGuard, Gummy Vites, Codral, ArthroGuard. Adcock’s customers include wholesale, retail and pharmaceutical multinationals. In FY2017, the company’s consumer segment generated revenues of ZAR688.8 million, which accounted for 11.9% of company’s total revenue excluding adjustments and eliminations. The company’s subsidiaries include the following: Adcock Ingram Limited, Adcock Ingram Healthcare Proprietary Limited, Adcock Ingram Intellectual Property Proprietary Limited, Adcock Ingram Critical Care Proprietary Limited, and Adcock Ingram Critical Care Proprietary Limited. Geographically, the company classifies its operations into two regions include Southern Africa and Rest of Africa. In FY2017, the Southern Africa reported 96.5% of company’s total revenue excluding adjustments and eliminations and Rest of Africa reported 3.5%.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757